A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Revised Protocol 01 incorporating Amendment 03

Bristol-Myers Squibb International Corporation0 个研究点目标入组 210 人开始时间: 2015年9月29日最近更新: 2017年10月2日

试验速览

暂无简介。

•1. JIA subjects (male or female), ages 2-17 years with active disease who had an insufficient therapeutic response or intolerance to at least one non biologic DMARD or TNFa antagonists for at least 3 months prior to screening
•2. Subjects with TNFa inadequate response (or prior biologic) will be restricted to 30% of the population
•3. Subjects must have a history of at least 5 joints with active disease and must have currently active articular disease with = 2 active joints and = 2 joints with limitation of motion.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 210
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Subjects with other rheumatic diseases or major chronic inflammatory/immunologic diseases, active uveitis, systemic JIA with active systemic features (within a period of 6 months prior to enrollment), persistent Oligoarthritis JIA, or failed 3 or more TNFa antagonists or other biological DMARDS will be excluded.
•2. Active systemic disease: (ie, extra-articular features of systemic JIA including fever, rash, organomegaly) within a period of 6 months prior to randomization.
•3. Subjects who have failed more than two TNFa antagonists or other biologic DMARDs

发起方